Efpeglenatide lowers risk for adverse CV events in T2DM
(HealthDay)—For patients with type 2 diabetes and a history of cardiovascular disease or current kidney disease, the risk for adverse cardiovascular events is lower with efpeglenatide, an exendin-based glucagon-like peptide ...
Jun 29, 2021
0
2